Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Inclusion Criteria: * HIV-1 RNA ≥ 5,000 copies/mL by Roche Amplicor assay * CD4 cell count ≥ 50 cells/mm3 * Karnofsky performance status ≥ 80 * Age ≥ 13 years * Screening laboratory values indicative of adequate baseline organ function, Grade 0 or 1 for laboratory values based on the ACTG toxicity scale grade. Selected stable \[2 months or longer\] Grade 2 laboratory abnormalities were subject to sponsor's approval * Acceptable medical history and physical examination * Agreement to use a barrier contraceptive method for at least 1 month prior to the administration of the study medication, during the study, and for 30 days after the end of the study * Signed informed consent * To enter the post-study option, patients have to have completed the 14-day tipranavir phase of the trial Exclusion Criteria: * Previous treatment with any antiretroviral drugs for more than 2 weeks * Clinically significant, active and/or acute (onset within the prior month) medical problems including opportunistic infections, such as active cryptococcosis, Pneumocystis carinii pneumonia (PCP), herpes zoster, histoplasmosis or cytomegalovirus (CMV) , or non-opportunistic diseases including, but not limited to, progressive multifocal leukoencephalopathy, lymphoma, or malignancy requiring systemic therapy * History of clinically significant nervous system or muscle diseases, seizure disorder, or psychiatric disorder that might impair compliance with the study * Receipt of any known enzyme-inducing drugs including rifabutin, rifampin, carbamazepine, dexamethasone, phenobarbital, phenytoin, sulfamidine, sulfinpyrazone, or troleandomycin within 30 days prior to participation in the study * Receipt of any investigational medication within 30 days prior to participation in the study * Receipt of oral contraceptives within 30 days prior to participation in the study * Pregnancy or lactation (serum ß-human chorionic gonadotropin (ß-HCG) test negative at second screen visit of the tipranavir phase of trial) * Evidence of active substance abuse that, in the investigator's opinion, could affect study adherence * In the investigator's judgment, inability to comply with the protocol requirements for reasons other than those specified above